Ruxolitinib Regulates the Autophagy Machinery in Multiple Myeloma Cells.


Kusoglu A., Bagca B. , Ozates A. , Saydam G. , Avci Ç.

Anti-cancer agents in medicinal chemistry, vol.20, no.18, pp.2316-2323, 2020 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 18
  • Publication Date: 2020
  • Doi Number: 10.2174/1871520620666200218105159
  • Title of Journal : Anti-cancer agents in medicinal chemistry
  • Page Numbers: pp.2316-2323
  • Keywords: Ruxolitinib, multiple myeloma, autophagy, Interleukin-6, JAK, STAT, PATHWAY, EXPRESSION, SURVIVAL, GROWTH, DEATH

Abstract

Background: Ruxolitinib is a selective JAK1/2 inhibitor approved by the FDA for myelofibrosis in 2014 and nowadays, comprehensive investigations on the potential of the agent as a targeted therapy for haematological malignancies are on the rise. In multiple myeloma which is a cancer of plasma cells, the Interleukin-6/JAK/STAT pathway is emerging as a therapeutic target since the overactivation of the pathway is associated with poor prognosis.